Quality of life in homebound people with advanced Parkinson's disease: feasibility and outcomes of an interdisciplinary home visit program

Objective: 1) To demonstrate the feasibility of an interdisciplinary home visit program (HVP) for advanced Parkinson’s disease (PD) providing expert, interdisciplinary care directly to homebound patients; 2) to test whether the HVP improves patient quality of life despite disease progression. Background: As PD progresses, symptoms increase, quality of life declines, and individuals may become homebound, often losing access to neurologic care. This leads to a surge in emergency department visits and hospitalizations. Improving access to expert in-home care may improve quality of life. Design/Methods: PD patients meeting Medicare criteria for homebound status are eligible to receive quarterly home visits over 12 months. Each visit entails an evaluation by a movement disorders specialist, social worker, and nurse, including detailed history, physical examination, real-time medication reconciliation, psychosocial evaluation, and referral to in-home services. Quality of life (Neuro-QoL) is measured at Visits 1 and 4. Results: Out of 27 subjects enrolled, 26 have completed the study. At baseline, subjects’ mean age is 81 years (SD 7.8); mean PD duration is 10 years; mean UPDRS total score is 65 (SD 20). Of the 26 subjects completing Visit 4, total UPDRS increased by a mean of 12 (SD 10.7), yet quality of life improved in 7/8 Neuro-QoL domains. Conclusions: We identified a unique population typically lost to clinical care and research—the elderly, homebound with advanced PD—and this is the first description of their progression over time. Despite the expected progression of functional and motor disability over one year, subjects reported improved quality of life since entering the HVP. Next steps include the implementation of a hybrid in-person/telehealth home visit model, inclusion of individuals with cognitive impairment in future studies, and comparison of outcomes with other advanced PD populations. Study Supported by: Edmond J. Safra Philanthropic Foundation; Parkinson Alliance; National Parkinson Foundation Disclosure: Dr. Fleisher has nothing to disclose. Dr. Sweeney has nothing to disclose. Dr. Oyler has nothing to disclose. Dr. Lemen has nothing to disclose. Dr. Meisel has nothing to disclose. Dr. Fazl has nothing to disclose. Dr. Dacpano has nothing to disclose. Dr. Gilbert has nothing to disclose. Dr. Di Rocco has nothing to disclose. Dr. Chodosh has nothing to disclose.